Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, Darby G
Manchester Public Health Laboratory, Withington Hospital, United Kingdom.
Antimicrob Agents Chemother. 1998 Apr;42(4):868-72. doi: 10.1128/AAC.42.4.868.
Acyclovir (ACV) has been used for more than 15 years in the management of herpes simplex virus (HSV) and varicella-zoster virus (VZV) disease. The present survey was undertaken to assess the level of ACV resistance in the population. More than 2,000 HSV isolates from both immunocompetent and immunocompromised patients in northwest England were collected over a 2-year period and tested for sensitivity to ACV. These studies suggested a prevalence of resistance of approximately 0.1 to 0.6% in immunocompetent individuals, with no apparent difference in prevalence between treated and untreated groups. In line with previous studies, the prevalence of resistance in treated immunocompromised individuals was approximately 6%.
阿昔洛韦（ACV）已用于治疗单纯疱疹病毒（HSV）和水痘-带状疱疹病毒（VZV）疾病超过15年。本次调查旨在评估人群中阿昔洛韦的耐药水平。在两年时间里，收集了来自英格兰西北部免疫功能正常和免疫功能低下患者的2000多株HSV分离株，并检测了它们对阿昔洛韦的敏感性。这些研究表明，免疫功能正常个体的耐药率约为0.1%至0.6%，治疗组和未治疗组的耐药率无明显差异。与先前的研究一致，接受治疗的免疫功能低下个体的耐药率约为6%。
